A Comparison Study of Ranibizumab and Aflibercept in Patients with Naive Diabetic Macular Edema in Presence of Serous Retinal Detachment

References

• Romero-Aroca P. Managing diabetic macular edema: the leading cause of diabetes blindness. World J Diabetes. 2011;2(6):98–104. doi:10.4239/wjd.v2.i6.98.
   PubMedGoogle Scholar
• Antonetti DA, Klein R, Gardner TW. Diabetic retinopathy. N Engl J Med. 2012;366(13):1227–39. Review. doi:10.1056/NEJMra1005073.
   PubMed Web of Science ®Google Scholar
• Otani T, Kishi S, Maruyama Y. Patterns of diabetic macular edema with optical coherence tomography. Am J Ophthalmol. 1999;127:688–93.
   PubMed Web of Science ®Google Scholar
• Kang SW, Park CY, Ham DI. The correlation between fluorescein angiographic and optical coherence tomographic features in clinically significant diabetic macular edema. Am J Ophthalmol. 2004;137(2):313–22. doi:10.1016/j.ajo.2003.09.016.
   PubMed Web of Science ®Google Scholar
• Spaide RF, Goldbaum M, Wong DW, Tang KC, Iida T. Serous detachment of the retina. Retina. 2003;23(6):820–46. quiz 895–6. Review.
   PubMed Web of Science ®Google Scholar
• Fogli S, Mogavero S, Egan CG, Del Re M, Danesi R. Pathophysiology and pharmacological targets of VEGF in diabetic macular edema. Pharmacol Res. 2016;103:149–57. doi:10.1016/j.phrs.2015.11.003.
   PubMed Web of Science ®Google Scholar
• Gao BB, Clermont A, Rook S, Fonda SJ, Srinivasan VJ, Wojtkowski M, Fujimoto JG, Avery RL, Arrigg PG, Bursell SE, et al. Extracellular carbonic anhydrase mediates hemorrhagic retinal and cerebral vascular permeability through prekallikrein activation. Nat Med. 2007;13(2):181–88. doi:10.1038/nm1534.
   PubMed Web of Science ®Google Scholar
• Huang H, Gandhi JK, Zhong X, Wei Y, Gong J, Duh EJ, Vinores SA. TNFalpha is required for late BRB breakdown in diabetic retinopathy, and its inhibition prevents leukostasis and protects vessels and neurons from apoptosis. Invest Ophthalmol Vis Sci. 2011;52(3):1336–44. doi:10.1167/iovs.10-5768.
   PubMed Web of Science ®Google Scholar
• Carmeliet P, Moons L, Luttun A, Vincenti V, Compernolle V, De Mol M, Wu Y, Bono F, Devy L, Beck H, et al. Synergism between vascular endothelial growth factor and placental growth factor contributes to angiogenesis and plasma extravasation in pathological conditions. Nat Med. 2001;7(5):575–83. doi:10.1038/87904.
   PubMed Web of Science ®Google Scholar
• Elman MJ, Aiello LP, Beck RW, Bressler NM, Bressler SB, Edwards AR, Ferris FL, Friedman SM, Glassman AR, Miller KM, et al. Randomized trial evaluating ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema. The diabetic retinopathy clinical research network. Ophthalmology. 2010 Jun;117(6):1064–77.e35. doi:10.1016/j.ophtha.2010.02.031.
   PubMed Web of Science ®Google Scholar
• Ajlan RS, Silva PS, Sun JK. Vascular endothelial growth factor and diabetic retinal disease. Semin Ophthalmol. 2016;31(1–2):40–48. Review. doi:10.3109/08820538.2015.1114833.
   PubMed Web of Science ®Google Scholar
• Nguyen QD, Brown DM, Marcus DM, Boyer DS, Patel S, Feiner L, Gibson A, Sy J, Rundle AC, Hopkins JJ, et al. Ranibizumab for diabetic macular edema: results from 2 phase III randomized trials: RISE and RIDE. Ophthalmology. 2012;119(4):789–801. doi:10.1016/j.ophtha.2011.12.039.
   PubMed Web of Science ®Google Scholar
• Brown DM, Schmidt-Erfurth U, Do DV, Holz FG, Boyer DS, Midena E, Heier JS, Terasaki H, Kaiser PK, Marcus DM, et al. Intravitreal aflibercept for diabetic macular edema: 100-week results from the VISTA and VIVID studies. Ophthalmology. 2015;122(10):2044–52. doi:10.1016/j.ophtha.2015.06.017.
   PubMed Web of Science ®Google Scholar
• Moradi A, Sepah YJ, Sadiq MA, Nasir H, Kherani S, Sophie R, Do DV, Nguyen QD. Vascular endothelial growth factor trap-eye (Aflibercept) for the management of diabetic macular edema. World J Diabetes. 2013;4(6):303–09. Review. doi:10.4239/wjd.v4.i6.303.
   PubMedGoogle Scholar
• Deissler HL, Lang GK, Lang GE. Capacity of aflibercept to counteract VEGF-stimulated abnormal behavior of retinal microvascular endothelial cells. Exp Eye Res. 2014;122:20–31. doi:10.1016/j.exer.2014.02.024.
   PubMed Web of Science ®Google Scholar
• Ozdemir H, Karacorlu M, Karacorlu S. Serous macular detachment in diabetic cystoid macular oedema. Acta Ophthalmol Scand. 2005;83(1):63–66. doi:10.1111/j.1600-0420.2005.00387.x.
   PubMedGoogle Scholar
• Ravalico G, Battaglia Parodi M. Exudative retinal detachment subsequent to retinal vein occlusion. Ophthalmologica. 1992;205:77–82. doi:10.1159/000310316.
   PubMed Web of Science ®Google Scholar
• Shukla D, Behera UC, Chakraborty S, Mahalakshmi R, Prasad NM. Serous macular detachment as a predictor of resolution of macular edema with intravitreal triamcinolone injection. Ophthalmic Surg Lasers Imaging. 2009;40:115–19.
   PubMedGoogle Scholar
• Shimura M, Yasuda K, Nakazawa T, Hirano Y, Sakamoto T, Ogura Y, Shiono T. Visual outcome after intravitreal triamcinolone acetonide depends on optical coherence tomographic patterns in patients with diffuse diabetic macular edema. Retina. 2011;31(4):748–54. doi:10.1097/IAE.0b013e3181f04991.
   PubMed Web of Science ®Google Scholar
• Gaucher D, Sebah C, Erginay A, Haouchine B, Tadayoni R, Gaudric A, Massin P. Optical coherence tomography features during the evolution of serous retinal detachment in patients with diabetic macular edema. Am J Ophthalmol. 2008;145(2):289–96. doi:10.1016/j.ajo.2007.09.029.
   PubMed Web of Science ®Google Scholar
• Koytak A, Altinisik M, Sogutlu Sari E, Artunay O, Umurhan Akkan JC, Tuncer K. Effect of a single intravitreal bevacizumab injection on different optical coherence tomographic patterns of diabetic macular oedema. Eye (Lond). 2013 Jun;27(6):716–21. doi:10.1038/eye.2013.17.
   PubMed Web of Science ®Google Scholar
• Shin HJ, Lee SH, Chung H, Kim HC. Association between photoreceptor integrity and visual outcome in diabetic macular edema. Graefe‘S Arch Clin Exp Ophthalmol. 2012;250(1):61–70. doi:10.1007/s00417-011-1774-x.
   PubMed Web of Science ®Google Scholar
• Forooghian F, Stetson PF, Meyer SA, Chew EY, Wong WT, Cukras C, Meyerle CB, Ferris FL 3rd. Relationship between photoreceptor outer segment length and visual acuity in diabetic macular edema. Retina. 2010;30(1):63–70. doi:10.1097/IAE.0b013e3181bd2c5a.
   PubMed Web of Science ®Google Scholar
• Ozdemir H, Karacorlu M, Karacorlu S. Regression of serous macular detachment after intravitreal triamcinolone acetonide in patients with diabetic macular edema. Am J Ophthalmol. 2005;140:251–55. doi:10.1016/j.ajo.2005.03.004.
   PubMed Web of Science ®Google Scholar
• Ohno-Matsui K, Yoshida T, Uetama T, Mochizuki M, Morita I. Vascular endothelial growth factor upregulates pigment epithelium-derived factor expression via VEGFR-1 in human retinal pigment epithelial cells. Biochem Biophys Res Commun. 2003;303:962–67. doi:10.1016/S0006-291X(03)00446-7.
   PubMed Web of Science ®Google Scholar
• Mitamura Y, Tashimo A, Nakamura Y, Tagawa H, Ohtsuka K, Mizue Y, Nishihira J. Vitreous levels of placenta growth factor and vascular endothelial growth factor in patients with proliferative diabetic retinopathy. Diabetes Care. 2002 Dec;25(12):2352. doi:10.2337/diacare.25.12.2352.
   PubMed Web of Science ®Google Scholar
• Jonas JB, Jonas RA, Neumaier M, Findeisen P. Cytokine concentration in aqueous humor of eyes with diabetic macular edema. Retina. 2012;32(10):2150–57. doi:10.1097/IAE.0b013e3182576d07.
   PubMed Web of Science ®Google Scholar
• Autiero M, Waltenberger J, Communi D, Kranz A, Moons L, Lambrechts D, Kroll J, Plaisance S, De Mol M, Bono F, et al. Role of PlGF in the intra- and intermolecular cross talk between the VEGF receptors Flt1 and Flk1. Nat Med. 2003;9(7):936–43. doi:10.1038/nm884.
   PubMed Web of Science ®Google Scholar
• Fouda SM, Bahgat AM. Intravitreal aflibercept versus intravitreal ranibizumab for the treatment of diabetic macular edema. Clin Ophthalmol. 2017 Mar 23;11:567–71. doi:10.2147/OPTH.S131381.
   PubMed Web of Science ®Google Scholar
• Wells JA, Ayala AR, Ayala AR, Jampol LM, Aiello LP, Antoszyk AN, Arnold-Bush B, Baker CW, Bressler NM, Browning DJ, et al. Diabetic retinopathy clinical research network. Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema. N Engl J Med. 2015;372(13):1193–203. doi:10.1056/NEJMoa1414264.
   PubMed Web of Science ®Google Scholar
• Shimizu N, Oshitari T, Tatsumi T, Takatsuna Y, Arai M, Sato E, Baba T, Yamamoto S. Comparisons of efficacy of intravitreal aflibercept and ranibizumab in eyes with diabetic macular edema. Biomed Res Int. 2017;2017:1747108. doi:10.1155/2017/1747108.
   PubMed Web of Science ®Google Scholar
• Grover D, Li TJ, Chong CC. Intravitreal steroids for macular edema in diabetes. Cochrane Database Syst Rev. 2008 Jan;23(1):CD005656. Review. doi:10.1002/14651858.CD005656.pub2.
   Web of Science ®Google Scholar
• Fraser-Bell S, Lim LL, Campain A, Mehta H, Aroney C, Bryant J, Li J, Quin GJ, McAllister IL, Gillies MC. Bevacizumab or dexamethasone Implants for DME: 2-year results (The BEVORDEX Study). Ophthalmology. 2016 Jun;123(6):1399–401. doi:10.1016/j.ophtha.2015.12.012.
   PubMed Web of Science ®Google Scholar
• Kaldırım H, Yazgan S, Atalay K, Gurez C, Savur F. Intravitreal dexamethasone implantation in patients with different morphological diabetic macular edema having insufficient response to ranibizumab. Retina. 2018 May;38(5):986–92. doi:10.1097/IAE.0000000000001648.
   PubMed Web of Science ®Google Scholar